Welcome to our dedicated page for Rocket Doctor AI news (Ticker: AIRDF), a resource for investors and traders seeking the latest updates and insights on Rocket Doctor AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rocket Doctor AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rocket Doctor AI's position in the market.
Rocket Doctor AI (OTC: AIRDF) closed its acquisition of Alea Health on Jan 8, 2026, under a definitive share purchase agreement dated Nov 19, 2025, as amended Dec 31, 2025.
The consideration included a US $15,000 acquisition deposit previously paid in cash, issuance of 285,712 common shares at a deemed CAD $0.70 per share, and assumption of a US $180,000 SAFE note to be paid in equal monthly installments of US $22,500, with the first installment paid at closing.
Consideration shares were issued under prospectus exemptions, are subject to a statutory hold period of four months and one day, and a 28-month escrow schedule releasing 20% every four months beginning on the first anniversary. No finder’s fees were paid and no long-term liabilities were assumed other than the SAFE note.
Rocket Doctor AI (OTC:AIRDF) announced a partnership with the CAN Health Network and Health Cities to pilot an AI-powered Clinical Decision Support System (CDSS) in Alberta.
The pilot runs from November 2025 to March 2026, will deploy at up to four primary care sites with about 20 clinicians, and phases include chatbot intake, real-time clinician support, and EMR integration. The company cites an expected 25–40% reduction in intake time, Canadian-hosted data centres compliant with HIPAA, PIPEDA, and Alberta HIA, and a Commercialization Project Agreement dated 11/12/2025. The project aims to validate CDSS performance and potentially scale across Alberta’s ~4,400 providers.
Rocket Doctor AI (CSE: AIDR | OTC: AIRDF) announced a management change and equity awards on Dec 5, 2025. Effective Dec 8, 2025, Christopher Cherry will become Interim Chief Financial Officer, replacing David Worner; Mr. Cherry currently serves as Chair of the Audit Committee.
The company granted an aggregate 579,028 stock options exercisable at $0.84 per share with terms of three or five years, and 931,112 restricted share units with terms of two to five years, to executives, directors and consultants. Awards are issued under the company’s share compensation plans and are subject to vesting conditions.
Rocket Doctor AI (OTC: AIRDF) announced a strategic partnership with Toronto Metropolitan University on December 4, 2025 to support clinical education using Rocket Doctor’s digital health platform.
Under the agreement, Rocket Doctor will promote clinical faculty appointments, verify physician status, facilitate learner observation (including virtual care), and coordinate physician applications. TMU will define faculty responsibilities, oversee placements, and maintain learning quality. The collaboration aims to expand teaching capacity across urban and underserved regions and modernize clinical training for medical learners in Ontario and Canada.
Rocket Doctor AI (OTC:AIRDF) reported Q3 2025 results showing continued sequential organic revenue growth and operational milestones. Revenue for Q3 2025 was $529,123 (up from $512,756 in Q2 2025 and $10,990 in Q3 2024). Gross margin was 88%. The company reported a net comprehensive loss of $3.5 million or $0.05 per share and Adjusted EBITDA loss of $1.8 million. Cash and equivalents improved to $1.89 million after an oversubscribed financing raising C$4.23 million. Corporate progress includes U.S. in‑network payer agreements extending reach to >13 million insured members and an NIH SBIR award of up to $500,000 USD for Treatment USA.
Rocket Doctor AI (OTC: AIRDF) announced that CEO Dr. Bill Cherniak spoke at the Google Accelerator Alumni Summit in Mexico City and presented at Heal.LA Accelerator Demo Day on Nov 26, 2025. As the only healthcare founder invited to speak, he discussed Rocket Doctor’s journey and the company's use of Google Gemini conversational models in its AI Nurse platform. Rocket Doctor AI says it is exploring expanded capabilities after the recent Gemini 3.0 launch and highlighted ongoing integration with Google Cloud and its proprietary Global Library of Medicine (GLM). The company remains focused on scaling clinically aligned AI tools and access to care into 2026.
Rocket Doctor AI (OTC: AIRDF) entered a definitive agreement to acquire 100% of Alea Health Holdings Ltd. on November 19, 2025. Consideration includes US$15,000 cash paid, 285,712 common shares (deemed CAD$0.70 each) and assumption of a US$180,000 SAFE note payable in US$22,500 monthly instalments. Alea’s conversational AI and voice-based mental‑health platform will be integrated with Rocket Doctor AI’s Global Library of Medicine to expand mental‑health capabilities and enter the UAE/GCC market.
Closing is subject to employment agreements, regulatory approvals including the CSE, and applicable shareholder approvals; securities will be issued under prospectus exemptions with hold periods and a 28‑month escrow schedule.
Rocket Doctor AI (OTC:AIRDF) granted an aggregate 831,356 restricted share units (RSUs) and 20,964 stock options to consultants and employees on Nov 7, 2025.
The Options are exercisable for one common share at an exercise price of C$0.82 per share for a three‑year term and are subject to vesting provisions and plan terms.
- RSU terms: 325,000 RSUs expire in two years; 506,356 RSUs expire in three years.
- Vesting: 203,000 RSUs vest immediately; 628,356 RSUs are subject to vesting provisions.
- All grants are subject to the company equity plans and applicable securities law hold periods.
Rocket Doctor (OTC:AIRDF) on Nov 5, 2025 announced four senior U.S. appointments to accelerate clinical operations, digital growth, and coast‑to‑coast expansion. New hires include Dr. Evan Ou as U.S. Medical Director, Dr. Sudha Kumar as U.S. MD Lead for Psychiatry, Dr. Mike Solemar as California MD Lead, and Jimmy Vannavong as Director of Growth. The hires target strengthened payer and community partnerships, expanded provider networks in key states, and data‑driven patient recruitment via AI-enabled marketing. The move follows recent payer credentialing in New York and California and aims to improve access in rural and underserved U.S. communities.
Rocket Doctor AI (OTC:AIRDF) announced engagement of Fundamental Research Corp for independent analyst coverage effective Oct 21, 2025.
FRC is described as a long‑standing independent small‑cap research firm with a 22‑year track record and coverage of 750+ companies; its reports are distributed via Reuters, Capital IQ, Bloomberg and by subscription.
Under the agreement FRC will deliver a full financial analysis including an Independent Analyst Rating, an initiating report, periodic updates and unlimited interim notes over an 18‑month term. The company paid FRC a fee of CAD$35,000 in connection with the engagement.
FAQ
What is the current stock price of Rocket Doctor AI (AIRDF)?
